Literature DB >> 34887602

Myotoxicity Induced by Antiepileptic Drugs: Could be a Rare but Serious Adverse Event?

Antonio Siniscalchi1, Scott Mintzer1, Giovambattista De Sarro1, Luca Gallelli1.   

Abstract

Antiepileptic drugs (AEDs) are used in various pathologies such as including epilepsy, migraine, neuropathic pain, etc. They can improve symptoms but cause adverse events (ADRs). Case reports have reported that one rare but serious AED-induced adverse reaction that has appeared in case reports is myotoxicity from rhabdomyolysis. Rhabdomyolysis can be induced by a therapeutically dosed occur with therapeutic doses of antiepileptic drugs and is in most cases reversible, although rarely it can cause serious complications. Clinical manifestations of rhabdomyolysis range from a single isolated asymptomatic rise in serum CK levels to severe electrolyte imbalances, cardiac arrhythmia, acute and disseminated renal failure, intravascular coagulation, and other symptoms. Many clinical cases reported that both conventional older and newer AEDs, as well as propofol, can cause rhabdomyolysis, even if there are no conclusive data. It has recently been shown that genetic factors certainly contribute to adverse reactions of antiepileptic drugs. A study of genetic polymorphism in patients with AED-induced rhabdomyolysis may be useful to explain the rarity of this adverse event and to improve the treatment of these AED patients, in terms of AED type and dose adjustment.
Copyright © 1964–2021 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  adverse events; antiepileptic drugs; genetic factors; myotoxicity; rhabdomiolysis

Mesh:

Substances:

Year:  2021        PMID: 34887602      PMCID: PMC8601760     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  93 in total

1.  Acute sodium valproate intoxication: occurrence of renal failure and treatment with haemoperfusion-haemodialysis.

Authors:  A M Roodhooft; K Van Dam; D Haentjens; G A Verpooten; K J Van Acker
Journal:  Eur J Pediatr       Date:  1990-02       Impact factor: 3.183

2.  Rhabdomyolysis of Multifactorial Origin in Schizophrenia: Antipsychotics, Statins, Trauma.

Authors:  Carlota Botillo-Martin; Emilio González-Pablos
Journal:  J Clin Psychopharmacol       Date:  2018-06       Impact factor: 3.153

Review 3.  Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children.

Authors:  J P Hanna; M L Ramundo
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

Review 4.  RYR1-related rhabdomyolysis: A common but probably underdiagnosed manifestation of skeletal muscle ryanodine receptor dysfunction.

Authors:  N C Voermans; M Snoeck; H Jungbluth
Journal:  Rev Neurol (Paris)       Date:  2016-09-20       Impact factor: 2.607

5.  Radiologic Findings in Gabapentin-Induced Myositis.

Authors:  Tyler Michael Coupal; David Ross Chang; Kevin Pennycooke; Hugue Alcide Ouellette; Peter Loren Munk
Journal:  J Radiol Case Rep       Date:  2017-04-30

6.  Rhabdomyolysis in children: a 3-year retrospective study.

Authors:  M C Chamberlain
Journal:  Pediatr Neurol       Date:  1991 May-Jun       Impact factor: 3.372

7.  Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy.

Authors:  Oktay Bilgir; Mehmet Calan; Ferda Bilgir; Levent Kebapçilar; Arif Yüksel; Yasar Yildiz; Ismail Sari
Journal:  Intern Med       Date:  2009-06-15       Impact factor: 1.271

8.  Stepwise approach to myopathy in systemic disease.

Authors:  Jasvinder Chawla
Journal:  Front Neurol       Date:  2011-08-05       Impact factor: 4.003

9.  Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid.

Authors:  Hongliang Li; Xueding Wang; Yafang Zhou; Guanzhong Ni; Qibiao Su; Ziyi Chen; Zhuojia Chen; Jiali Li; Xinmeng Chen; Xiangyu Hou; Wen Xie; Shuang Xin; Liemin Zhou; Min Huang
Journal:  Int J Neuropsychopharmacol       Date:  2015-03-03       Impact factor: 5.176

10.  Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis.

Authors:  N Dlamini; N C Voermans; S Lillis; K Stewart; E-J Kamsteeg; G Drost; R Quinlivan; M Snoeck; F Norwood; A Radunovic; V Straub; M Roberts; A F J E Vrancken; W L van der Pol; R I F M de Coo; A Y Manzur; S Yau; S Abbs; A King; M Lammens; P M Hopkins; S Mohammed; S Treves; F Muntoni; E Wraige; M R Davis; B van Engelen; H Jungbluth
Journal:  Neuromuscul Disord       Date:  2013-04-28       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.